Bank of New York Mellon Corp - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 145 filers reported holding CTI BIOPHARMA CORP in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q1 2023$1,373,577
-31.5%
327,042
-1.9%
0.00%
Q4 2022$2,004,479
-7.3%
333,524
-10.2%
0.00%
-100.0%
Q3 2022$2,162,000
-26.8%
371,489
-24.9%
0.00%0.0%
Q2 2022$2,954,000
+261.1%
494,831
+182.7%
0.00%
Q1 2022$818,000
+1158.5%
175,057
+564.8%
0.00%
Q4 2021$65,000
-16.7%
26,3320.0%0.00%
Q3 2021$78,000
+18.2%
26,3320.0%0.00%
Q2 2021$66,000
-14.3%
26,3320.0%0.00%
Q1 2021$77,000
-17.2%
26,332
-9.1%
0.00%
Q4 2020$93,000
-41.5%
28,970
-82.4%
0.00%
Q1 2019$159,000
+43.2%
164,695
+9.3%
0.00%
Q4 2018$111,000
-65.8%
150,673
+0.0%
0.00%
Q3 2018$325,000
-56.7%
150,6710.0%0.00%
Q2 2018$750,000
+288.6%
150,671
+203.7%
0.00%
Q1 2018$193,000
+232.8%
49,616
+129.2%
0.00%
Q4 2017$58,000
-15.9%
21,645
+0.0%
0.00%
Q3 2017$69,000
-4.2%
21,6430.0%0.00%
Q2 2017$72,000
-20.9%
21,6430.0%0.00%
Q1 2017$91,00021,6430.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q4 2022
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 4,068,191$4,719,0009.14%
CAXTON CORP 619,460$719,0000.76%
BVF INC/IL 6,929,690$8,038,0000.50%
NEA Management Company, LLC 7,140,450$8,283,0000.33%
Orbimed Advisors 9,520,600$11,044,0000.16%
Renaissance Technologies 2,103,792$2,440,0000.00%
Paloma Partners Management Co 30,289$35,0000.00%
WEDBUSH SECURITIES INC 12,600$15,0000.00%
HRT FINANCIAL LP 19,710$22,0000.00%
FIRST MANHATTAN CO. LLC. 33$00.00%
View complete list of CTI BIOPHARMA CORP shareholders